Friedrich von Bohlen und Halbach
Director/Board Member at HEIDELBERG PHARMA AG
Profile
Friedrich von Bohlen und Halbach founded Lion Bioscience AG in 1997, where he worked as Chief Executive Officer from 1997 to 2003 and Molecular Health GmbH in 2004, where he is working as Chief Executive Officer & Managing Director.
Dr. von Bohlen und Halbach also founded Posbelduf Biotech AG, where he worked as Chairman & Chief Executive Officer.
Dr. von Bohlen und Halbach also currently works at Apogenix AG, as Chairman-Supervisory Board, Molecular Health, Inc., as Executive Chairman, Novaliq GmbH, as Chairman-Supervisory Board, and various other companies.
Dr. von Bohlen und Halbach also formerly worked at GPC Biotech AG, as Chief Executive Officer, Wasag Chemie AG, as Chief Executive Officer from 1994 to 1997, 2invest AG, as Deputy Chairman-Supervisory Board, and various other companies.
Dr. von Bohlen und Halbach received his doctorate degree in 1992 from Swiss Federal Institute of Technology.
Friedrich von Bohlen und Halbach active positions
Companies | Position | Start |
---|---|---|
HEIDELBERG PHARMA AG | Director/Board Member | 2005-04-28 |
Wyss Translational Center Zurich | Corporate Officer/Principal | - |
dievini Hopp BioTech holding GmbH & Co. KG
dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Private Equity Investor | 2004-12-31 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Director/Board Member | - |
Novaliq GmbH
Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Chairman | - |
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Chairman | - |
Molecular Health, Inc.
Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Chairman | - |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Director/Board Member | - |
Molecular Health GmbH
Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The private company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Chief Executive Officer | 2003-12-31 |
░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Former positions of Friedrich von Bohlen und Halbach
Companies | Position | End |
---|---|---|
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Friedrich von Bohlen und Halbach
Swiss Federal Institute of Technology | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 7 |
---|---|
FRESENIUS SE & CO. KGAA | Health Technology |
2INVEST AG | Finance |
AC IMMUNE SA | Health Technology |
HEIDELBERG PHARMA AG | Health Technology |
COSMO PHARMACEUTICALS N.V. | Health Technology |
IMMATICS N.V. | Health Technology |
CUREVAC N.V. | Health Technology |
Private companies | 26 |
---|---|
Cosmo Pharmaceuticals SA
Cosmo Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Cosmo Pharmaceuticals SA operates as a pharmaceutical company that engages in the manufacturing of pharmaceutical drugs. It focuses on the development of gastro-intestinal pharmaceutical products for the treatment of inflammatory bowel diseases, colon infections and colon diagnosis, and treated skin disorders. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Lainate, Italy. | Health Technology |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
GPC Biotech AG
GPC Biotech AG Miscellaneous Commercial ServicesCommercial Services GPC Biotech AG is a biotechnology company discovering and developing new anticancer drugs.It is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has research and development sites in Waltham, Massachusetts and Princeton, New Jersey | Commercial Services |
Wasag Chemie AG | Process Industries |
Integrated Diagnostics, Inc.
Integrated Diagnostics, Inc. Medical/Nursing ServicesHealth Services Integrated Diagnostics, Inc. operates as a molecular diagnostics firm. It develops diagnostics and measurement technologies that has a capability of measuring biomarkers for diagnosis and management of complex diseases. The company was founded by Jim Heath, David J. Galas, Leroy E. Hood, and Paul Edward Kearney and is headquartered Seattle, WA. | Health Services |
Curacyte AG
Curacyte AG Miscellaneous Commercial ServicesCommercial Services Curacyte AG develops and markets biopharmaceutical solutions. The firm specializes in the development of new therapeutics for acute and critical care applications. Its focus areas cover applications in hematology, antithrombosism, and oncology. Its pipeline and development portfolio encompasses technologies, such as hemoximers, distributive shock, cardiogenic shock, plasmin and plasma kallikrei, matriptase, and high-dose interleukin-2 therapy. The company was founded in February 2000 and is headquartered in Munich, Germany. | Commercial Services |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Private Life BioMed AG
Private Life BioMed AG Investment ManagersFinance Private Life BioMed AG is a venture capital firm established in 2000 and located in Hamburg. The firm is a subsidiary of M.M. Warburg & Co. KGaA, a Hamburg-based private and investment bank. | Finance |
Cosmo Holding SpA
Cosmo Holding SpA Pharmaceuticals: MajorHealth Technology Cosmo Holding SpA manufactures and markets pharmaceutical products. It develops technologies in the sector of modified drug release with oral, topical, and transmucosal applications. The company was founded in 1996 and is headquartered in Milan, Italy. | Health Technology |
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Health Technology |
dievini Hopp BioTech holding GmbH & Co. KG
dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Finance |
Agennix AG
Agennix AG BiotechnologyHealth Technology Agennix AG was a pharmaceutical company, which engaged in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs included oral talactoferrin alfa and RGB-286638. The company was founded in 1993 and was headquartered in Heidelberg, Germany. | Health Technology |
Febit, Inc. | |
Weinheim 216 GmbH & Co. KG
Weinheim 216 GmbH & Co. KG BiotechnologyHealth Technology Weinheim 216 GmbH & Co. KG operates as a cellular therapy company involving primary human hepatocytes. The company is headquartered in Weinheim, Germany. | Health Technology |
Cosmo Bioscience SpA | |
Posbelduf Biotech AG
Posbelduf Biotech AG Pharmaceuticals: MajorHealth Technology Molecular Health AG provides clinico-molecular informatic solutions. The firm’s approach allows doctors translate patient-specific molecular and genomic data, clinical history, and published scientific evidence into drug choices. The company was founded by Friedrich von Bohlen in 2004 and is headquartered in Basel, Switzerland. | Health Technology |
Lion Bioscience AG | |
dievini Verwaltungs GmbH | |
Molecular Health GmbH
Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The private company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Commercial Services |
Molecular Health, Inc.
Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Technology Services |
Novaliq GmbH
Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Health Technology |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Health Technology |
Wyss Translational Center Zurich | |
Innosource Ventures AG | |
febit holding GmbH
febit holding GmbH Medical/Nursing ServicesHealth Services febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany. | Health Services |
Heidelberg Pharma AG /Old/
Heidelberg Pharma AG /Old/ Miscellaneous Commercial ServicesCommercial Services Heidelberg Pharma AG provides drug development services. The firm also provides services for the pre-clinical development of new chemical or biological entities, which includes drug metabolism- and pharmacokinetic (DMPK) studies and pharmacology services in the field of cancer, inflammatory and autoimmune diseases. The company was founded in 1999 and is headquartered in Ladenburg, Germany. | Commercial Services |
- Stock Market
- Insiders
- Friedrich von Bohlen und Halbach